Detailed description page of THPdb

Details of Th1150 which contains 1 entries.

Entry 1
(1) Primary information
ID 1654
ThPP ID Th1150
Therapeutic Peptide/Protein Name Secukinumab
Sequence Secukinumab Heavy Chain:EVQLVESGGGLVQPGGSLRLSCAASG view full sequnce in fasta
Functional Classification IIa
Molecular Weight 147940
Chemical Formula C6584H10134N1754O2042S44
Isoelectric Point N.A.
Hydrophobicity N.A.
Melting Point (℃) N.A.
Half Life N.A.
Description A human monoclonal antibody, secukinumab (cosentyx) was designed for the treatment of uveitis, rheumatoid arthritis, ankylosing spondylitis, and psoriasis. Secukinumab is an interleukin-17A inhibitor marketed by Novartis. On January 19, 2015, secukinumab was approved by the European Commission as a first line systemic treatment in moderate to severe adult plaque psoriasis. On January 21, 2015, the United States Food and Drug Administration announced that it had approved secukinumab to treat adults with moderate-to-severe plaque psoriasis.
Indication/Disease ItÂ is a human interleukin-17A antagonist indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.
Pharmacodynamics Elevated levels of IL-17A are found in psoriatic plaques. Treatment with cosentyx may reduce epidermal neutrophils and IL-17A levels in psoriatic plaques. Serum levels of total IL-17A (free and secukinumab-bound IL-17A) measured at Week 4 and Week 12 were increased following secukinumab treatment. These pharmacodynamic activities are based on small exploratory studies. The relationship between these pharmacodynamic activities and the mechanism(s) by which secukinumab exerts its clinical effects is unknown.
Mechanism of Action Secukinumab is a human IgG1 monoclonal antibody that selectively binds to the interleukin-17A (IL-17A) cytokine and inhibits its interaction with the IL-17 receptor. IL-17A is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. Secukinumab inhibits the release of proinflammatory cytokines and chemokines.
Toxicity N.A.
Metabolism N.A.
Absorption N.A.
Volume of Distribution N.A.
Clearance N.A.
Categories Inhibitor
Patents Number US20130202610
Date of Issue 10/08/10
Date of Expiry 10/08/20
Drug Interaction N.A.
Target IL-17A cytokine
Information of corresponding available drug in the market
Brand Name Cosentyx
Company Novartis Pharmaceuticals Corporation
Brand Discription Secukinumab is aÂ recombinantÂ humanÂ monoclonalÂ IgG1/Îº antibody that binds specifically to IL-17A. It is expressed in a recombinant Chinese Hamster Ovary (CHO) cell line. Secukinumab has a molecular mass of approximately 151 kDa; both heavy chains of secukinumab contain oligosaccharide chains.
Prescribed for CosentyxÂ is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.
Chemical Name N.A.
Formulation Each cosentyx sensoready pen or prefilled syringe contains 150 mg of secukinumab formulated in: Lhistidine/Â histidineÂ hydrochloride monohydrate (3.103 mg), L-methionineÂ (0.746 mg), polysorbate 80 (0.2 mg), trehalose dihydrate (75.67 mg), and Sterile Water for Injection, USP, at pH of 5.8.
Physcial Appearance Cosentyx injection is a sterile, preservative-free, clear to slightly opalescent, colorless to slightly yellow solution.
Route of Administration Subcutaneous injection
Recommended Dosage The recommended dose is 300 mg by subcutaneous injection at Weeks 0, 1, 2, 3, and 4 followed by 300 mg every 4 weeks. Each 300 mg dose is given as 2 subcutaneous injections of 150 mg. For some patients, a dose of 150 mg may be acceptable.
Contraindication Patients with a previous serious hypersensitivity reaction to secukinumab or to any of the excipientsÂ
Side Effects Crohnâ€™s disease â€œflare-upsâ€ (worsening Crohnâ€™s disease), serious allergic reactions, chest tightness, swelling of your face, eyelids, lips, mouth, tongue, or throat, trouble breathing or throat tightness, skin rash and upper respiratory infections
Useful Link http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=77c4b13e-7df3-42d4-81db-3d0cddb7f67a#section-10
PubMed ID 23361084
3-D Structure N.A.

OSDDlinux

Raghava's Group

IMTECH

CSIR

CRDD
CPPSITE 2.0

(1) Primary information
Entry 1
ID	1654
ThPP ID	Th1150
Therapeutic Peptide/Protein Name	Secukinumab
Sequence	Secukinumab Heavy Chain:EVQLVESGGGLVQPGGSLRLSCAASG view full sequnce in fasta
Functional Classification	IIa
Molecular Weight	147940
Chemical Formula	C6584H10134N1754O2042S44
Isoelectric Point	N.A.
Hydrophobicity	N.A.
Melting Point (℃)	N.A.
Half Life	N.A.
Description	A human monoclonal antibody, secukinumab (cosentyx) was designed for the treatment of uveitis, rheumatoid arthritis, ankylosing spondylitis, and psoriasis. Secukinumab is an interleukin-17A inhibitor marketed by Novartis. On January 19, 2015, secukinumab was approved by the European Commission as a first line systemic treatment in moderate to severe adult plaque psoriasis. On January 21, 2015, the United States Food and Drug Administration announced that it had approved secukinumab to treat adults with moderate-to-severe plaque psoriasis.
Indication/Disease	ItÂ is a human interleukin-17A antagonist indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.
Pharmacodynamics	Elevated levels of IL-17A are found in psoriatic plaques. Treatment with cosentyx may reduce epidermal neutrophils and IL-17A levels in psoriatic plaques. Serum levels of total IL-17A (free and secukinumab-bound IL-17A) measured at Week 4 and Week 12 were increased following secukinumab treatment. These pharmacodynamic activities are based on small exploratory studies. The relationship between these pharmacodynamic activities and the mechanism(s) by which secukinumab exerts its clinical effects is unknown.
Mechanism of Action	Secukinumab is a human IgG1 monoclonal antibody that selectively binds to the interleukin-17A (IL-17A) cytokine and inhibits its interaction with the IL-17 receptor. IL-17A is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. Secukinumab inhibits the release of proinflammatory cytokines and chemokines.
Toxicity	N.A.
Metabolism	N.A.
Absorption	N.A.
Volume of Distribution	N.A.
Clearance	N.A.
Categories	Inhibitor
Patents Number	US20130202610
Date of Issue	10/08/10
Date of Expiry	10/08/20
Drug Interaction	N.A.
Target	IL-17A cytokine
Information of corresponding available drug in the market
Brand Name	Cosentyx
Company	Novartis Pharmaceuticals Corporation
Brand Discription	Secukinumab is aÂ recombinantÂ humanÂ monoclonalÂ IgG1/Îº antibody that binds specifically to IL-17A. It is expressed in a recombinant Chinese Hamster Ovary (CHO) cell line. Secukinumab has a molecular mass of approximately 151 kDa; both heavy chains of secukinumab contain oligosaccharide chains.
Prescribed for	CosentyxÂ is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.
Chemical Name	N.A.
Formulation	Each cosentyx sensoready pen or prefilled syringe contains 150 mg of secukinumab formulated in: Lhistidine/Â histidineÂ hydrochloride monohydrate (3.103 mg), L-methionineÂ (0.746 mg), polysorbate 80 (0.2 mg), trehalose dihydrate (75.67 mg), and Sterile Water for Injection, USP, at pH of 5.8.
Physcial Appearance	Cosentyx injection is a sterile, preservative-free, clear to slightly opalescent, colorless to slightly yellow solution.
Route of Administration	Subcutaneous injection
Recommended Dosage	The recommended dose is 300 mg by subcutaneous injection at Weeks 0, 1, 2, 3, and 4 followed by 300 mg every 4 weeks. Each 300 mg dose is given as 2 subcutaneous injections of 150 mg. For some patients, a dose of 150 mg may be acceptable.
Contraindication	Patients with a previous serious hypersensitivity reaction to secukinumab or to any of the excipientsÂ
Side Effects	Crohnâ€™s disease â€œflare-upsâ€ (worsening Crohnâ€™s disease), serious allergic reactions, chest tightness, swelling of your face, eyelids, lips, mouth, tongue, or throat, trouble breathing or throat tightness, skin rash and upper respiratory infections
Useful Link	http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=77c4b13e-7df3-42d4-81db-3d0cddb7f67a#section-10
PubMed ID	23361084
3-D Structure	N.A.